Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13168443 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL21497288 | 0.86 | PAOX (0.54) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL26382167 | 0.86 | PAOX (0.54) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL21099785 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL26383496 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL9283986 | 0.82 | ALDH1A1 (0.54) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL23847104 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL16261366 | 0.80 | PAOX (0.48) | SMN1; SMN2ALDH1A1MAPTLMNAPAOX | |
| SCHEMBL12428915 | 0.80 | KDM4E (0.55) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL803688 | 0.80 | ALDH1A1 (0.57) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9604999-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | SMN1; SMN2 1750/4885GLA 1581/4885KMT2A 2160/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | SMN1; SMN2 855/4885GLA 241/4885KMT2A 2879/4885 |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SLC7A1, SLC7A5, SLC43A1 | SMN1; SMN2 2084/4885GLA 2527/4885KMT2A 1095/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | SMN1; SMN2 1639/4885GLA 2943/4885KMT2A 1947/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | SMN1; SMN2 1176/4885GLA 252/4885KMT2A 2167/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | SMN1; SMN2 2041/4885GLA 326/4885KMT2A 3596/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | SMN1; SMN2 3416/4885GLA 3590/4885KMT2A 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.